Alnylam closes enrolment in Phase III trial of vutrisiran
Alnylam Pharmaceuticals has completed patient enrolment in the Phase III HELIOS-A clinical trial of vutrisiran for the treatment of hereditary transthyretin (hATTR) amyloidosis.
Rybelsus (Semaglutide) for the Treatment of Type 2 Diabetes
Rybelsus® (semaglutide) is the first oral glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes in adult patients.
Boehringer Ingelheim reports positive CV data of linagliptin
Boehringer Ingelheim has reported positive data from a subgroup analysis of the CARMELINA clinical trial of linagliptin in type 2 diabetes patients.
Moderna enrols first patient in Phase I/II trial of mRNA-3704
Clinical-stage biotechnology firm Moderna has enrolled the first patient in the Phase I/II trial of mRNA-3704 in methylmalonic acidemia (MMA) patients.
Ionis and Akcea announce positive data for hypertriglyceridemia
Ionis Pharmaceuticals and its affiliate Akcea Therapeutics have reported positive data from the Phase II clinical trial of AKCEA-APOCIII-L conducted in hypertriglyceridemia patients with or at risk of cardiovascular disease (CVD).
Akero to expand ongoing Phase IIa trial of AKR-001 for NASH
Akero Therapeutics is set to expand the ongoing Phase IIa BALANCED study of Fc-FGF21 fusion protein AKR-001 to include an additional cohort of subjects with non-alcoholic steatohepatitis (NASH) who have compensated cirrhosis (F4), Child-Pugh Class A.
Lipaglyn (Saroglitazar) for Treating Hypertriglycerdemia in Type II Diabetes
Lipaglyn™ (Saroglitazar) is a dual peroxisome proliferator-activated receptor (PPAR) agonist indicated for the treatment of hypertriglyceridemia in Type II diabetics.
Applied Therapeutics reports positive results from Galactosemia study
Applied Therapeutics has reported positive results from a Phase II portion of ACTION-Galactosemia study of AT-007 in adult Galactosemia patients.
Boehringer Ingelheim ends BI 1467335 development for NASH
Boehringer Ingelheim has discontinued BI 1467335 development for non-alcoholic steatohepatitis (NASH) treatment after reviewing results from a Phase I clinical trial.